2,4-diaminopyrimidine has been researched along with Lung Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Achary, R; Hwang, JY; Kim, HR; Kim, P; Lee, CO; Lee, DH; Mathi, GR; Park, CH; Yun, CS | 1 |
| Cai, Y; Chen, L; Ding, J; Fang, B; Feng, C; Feng, J; Fu, W; Hu, J; Liang, G; Liu, Z; Qiu, Y; Qu, R; Tong, L; Xie, H; Zheng, L | 1 |
| Ahn, S; Hwang, JY; Kim, HR; Lee, CO; Lee, M; Park, CH; Song, D; Yun, CS | 1 |
3 other study(ies) available for 2,4-diaminopyrimidine and Lung Neoplasms
| Article | Year |
|---|---|
Novel 2,4-diaminopyrimidines bearing fused tricyclic ring moiety for anaplastic lymphoma kinase (ALK) inhibitor.
Topics: Administration, Oral; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, SCID; Protein Kinase Inhibitors; Pyrimidines; Receptor Protein-Tyrosine Kinases; Transplantation, Heterologous | 2017 |
Structure-based design and synthesis of 2,4-diaminopyrimidines as EGFR L858R/T790M selective inhibitors for NSCLC.
Topics: Animals; Cell Line, Tumor; ErbB Receptors; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Molecular Structure; Pyrimidines; Small Cell Lung Carcinoma; Structure-Activity Relationship | 2017 |
Novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety against anaplastic lymphoma kinase (ALK): Synthesis, in vitro, ex vivo, and in vivo efficacy studies.
Topics: Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Humans; Lung; Lung Neoplasms; Male; Mice; Mice, SCID; Naphthalenes; Protein Kinase Inhibitors; Pyrimidines; Rats; Receptor Protein-Tyrosine Kinases | 2016 |